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Abstract 
Background: Indications for red blood cell (RBC) transfusion in septic acute circulatory failure remain unclear. We 
addressed the practices and the prognostic impact of RBC transfusion in the early resuscitation of severe sepsis and 
septic shock in patients with hematological malignancies.
Methods: We performed a retrospective analysis of a prospectively collected database of patients with hematologi‑
cal malignancies who required intensive care unit (ICU) admission in 2010–2011. Patients with a main admission 
diagnosis of severe sepsis or septic shock were included in the present study. We assessed RBC transfusion during the 
first two days as part of initial resuscitation.
Results: Among the 1011 patients of the primary cohort, 631 (62.4%) were admitted to the ICU for severe sepsis 
(55%) or septic shock (45%). Among them, 210 (33.3%) patients received a median of 2 [interquartile 1–3] packed red 
cells during the first 48 h. Hemoglobin levels were lower in transfused patients at days 1 and 2 and became similar to 
those of non‑transfused patients at day 3. Early RBC transfusion was more likely in patients with myeloid neoplasms 
and neutropenia. Transfused patients displayed more severe presentations as assessed by higher admission SOFA 
scores and blood lactate levels and the further requirements for organ failure supports. RBC transfusion within the first 
two days was associated with higher day 7 (20.5 vs. 13.3%, p = 0.02), in‑ICU (39 vs. 25.2%, p < 0.001) and in‑hospital 
(51 vs. 36.6%, p < 0.001) mortality rates. RBC transfusion remained independently associated with increased in‑hospi‑
tal mortality in multivariate logistic regression (OR 1.52 [1.03–2.26], p = 0.03) and propensity score‑adjusted (OR 1.64 
[1.05–2.57], p = 0.03) analysis.
Conclusions: RBC transfusion is commonly used in the early resuscitation of septic patients with hematological 
malignancies. Although it was preferentially provided to the most severe patients, we found it possibly associated 
with an increased risk of death.
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Background
Septic shock is a frequent and dreaded complication 
in patients with malignancies. Following the overall 
improvement in the management of the disease, the last 
two decades have witnessed dramatic improvements in 
the prognosis of cancer patients presenting with severe 
sepsis and septic shock [1–4]. A major advance in the 
general management of sepsis was the implementation 
of aggressive resuscitation strategies, primarily inspired 
from the pivotal study by Rivers and colleagues, which 
promoted a protocol-guided hemodynamic resuscitation 
based on circulatory and tissue oxygenation objectives, 
the so-called early goal-directed therapy (EGDT) [5]. The 
genuine EGDT algorithm included a hematocrit target 
of 30% in case of persistent tissue hypoxia. Two-thirds of 
EGDT-treated patients therefore received red blood cell 
(RBC) transfusion within the early 72 h of resuscitation. 
However, the own prognostic value of RBC transfusion 
was not specifically assessed. Moreover, the study was 
performed in the late 1990s at the time when liberal fluid 
filling accounted for a high incidence of dilution anemia. 
All three recent replication studies of early goal-directed 
therapy retrieved lower requirements in RBC transfusion 
along with a more restrictive fluid filling policy [6–8]. 
Indications of RBC transfusion in the resuscitation of 
severe sepsis remain unclear [9], and it is noteworthy that 
the 2012 Surviving Sepsis Campaign guidelines were not 
able to provide any firm recommendation about the opti-
mal transfusion threshold during hemodynamic insta-
bility [10]. Owing to the remaining controversy about 
optimal hemoglobin thresholds for transfusion in sep-
sis resuscitation, additional data are needed to optimize 
practices at the bedside.
Cancer patients with septic shock are at high risk of 
untractable multiple organ failure within the first days of 
ICU admission [11]. Early and aggressive resuscitation 
through restoration of both hemodynamics and tissue 
oxygenation is a major therapeutic goal in this setting. 
The optimal threshold for RBC transfusion and the even-
tual benefit in septic acute circulatory failure are debated. 
This issue appears particularly relevant to patients with 
hematological malignancies since the high prevalence of 
anemia imposed by malignant bone marrow infiltration 
or by cytotoxic treatments makes them particularly liable 
to urgent RBC transfusion in this setting in contrast to 
patients with delayed ICU-acquired anemia. This ques-
tion was not specifically addressed by the leading trials 
about transfusion strategies in critically ill patients, since 
patients with chronic anemia were excluded from the 
pivotal TRICC trial and cancer patients were underrep-
resented in the TRISS trial [12–14]. We herein addressed 
the practices and the prognostic value of RBC transfu-
sion as part of early sepsis resuscitation in a large cohort 
of patients with hematological malignancies who were 
admitted to the intensive care unit (ICU) for the main 
diagnosis of severe sepsis and septic shock.
Patients and methods
Study design
We conducted a substudy of a prospective, multicenter 
observational study that included 1011 consecutive adult 
patients with hematological malignancies who required 
ICU admission in 2010–2011. The study was approved 
by the appropriate ethics committees in France and 
Belgium. The methods and primary results of the study 
have been already published elsewhere [15]. The study 
involved 17 centers in France and Belgium, which may 
display different transfusion practices toward patients 
with hemodynamic instability. Blood banks followed sim-
ilar national procedures for the collection, pre-storage 
leucoreduction, storage duration and delivery of RBC 
concentrates.
Patients
We focused on patients with a primary diagnosis of 
severe sepsis or septic shock according to the common 
definitions of the Surviving Sepsis Campaign [10]. Briefly, 
severe sepsis was defined by a clinically or microbiologi-
cally documented infection associated with organ failure. 
Septic shock was defined as an acute circulatory failure 
requiring vasopressor support. We collected the require-
ments for RBC transfusion during the first 48  h as part 
of initial resuscitation, thereby identifying transfused and 
non-transfused patients.
The following data were prospectively collected: demo-
graphic features (age and gender), performance status 
prior to the acute complication, comorbidities using the 
Charlson comorbidity index, features of the underlying 
hematological malignancy (type of disease, time from 
diagnosis, status, hematopoietic stem cell transplanta-
tion). Newly diagnosed malignancies were defined as 
diagnosed within the past 4  weeks. The sepsis-related 
organ failure assessment (SOFA) score was computed 
on admission then daily throughout the stay in the ICU 
[16]. The features and management features of sepsis 
included the primary source of infection and the patho-
gen involved, as well as requirements for life-supporting 
interventions including vasopressor support, noninva-
sive/invasive mechanical ventilation and renal replace-
ment therapy during the ICU stay.
Statistical analysis
Quantitative variables were described as median [inter-
quartile range] and categorical variables as number 
(percentage). The primary endpoint was vital status at 
hospital discharge. Multivariate logistic regression was 
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used to assess the impact of day 1–2 transfusion on hos-
pital mortality. The covariates identified as determinants 
of death in the primary analyses were entered into the 
model. Log-linearity was checked for continuous vari-
ables. Non-log-linear variables were dichotomised. Hos-
mer–Lemeshow goodness-of-fit tests were performed on 
multivariate regression models.
In order to limit bias in between-group comparisons, a 
propensity score-based approach was used to assess the 
impact of transfusion on hospital mortality, ICU mortal-
ity and 7-day mortality. The propensity score was defined 
as the probability that a patient with specific baseline 
characteristics receives transfusion. Then, two patients 
with identical propensity score values can be considered 
as comparable, and matching on the propensity score 
has been shown as one of the most efficient method for 
treatment effect assessment. We computed the propen-
sity score using logistic regression to predict transfusion 
based on baseline characteristics known to be linked to 
the mortality and/or possibly to transfusion. Each subject 
treated by transfusion was randomly selected and then 
matched (without replacement) to the nearest untreated 
subject based on calipers of width of 0.2 of the standard 
deviation of the logit of the propensity score [17]. An 
inverse probability weighting approach for propensity 
score was also considered as sensitivity analysis. Missing 
data were handled using multiple imputation by chained 
equation. Fifty complete dataset were created using 10 
iterations of the chained equation process. Rubin’s rules 
were applied after the evaluation of the treatment effect 
on each complete dataset.
All tests were two-sided and p values <0.05 were con-
sidered as indicating significant association. Analyses 
were performed using the R statistical software version 
2.15.0 (http://www.Rproject.org).
Results
Among the 1011 patients of the primary cohort, 347 
(34.3%) were admitted to the ICU for severe sepsis and 
284 (28%) for septic shock. Of those 631 patients, 210 
(33%) received transfusions of 2 [1–3] packed red cells 
as part of the initial resuscitation strategy during the first 
two days in the ICU (148 (23.5%) and 89 (14.5%) at days 
1 and 2, respectively). Among transfused patients, 6 (3%) 
presented concurrent bleeding at the time of admission. 
Hemoglobin levels were lower in transfused patients at 
day 1 (7.8 [7.1–8.8] vs. 9.7 [8.7–11] g/dL, p < 0.001) and 
day 2 (8.9 [7.9–9.9] vs. 9.3 [8.4–10.2] g/dL, p  =  0.001) 
and became similar to those of non-transfused patients at 
day 3 (8.9 [8.2–9.8] vs. 8.9 [8–10]) (Fig. 1).
The other characteristics of non-transfused and trans-
fused patients are shown and compared in Table 1. Early 
RBC transfusion was more likely in patients with acute 
myeloid leukemia and neutropenia. Transfused patients 
appeared with more severe presentations and tissue 
dysoxia as assessed by higher admission SOFA scores (8 
[5–11] vs. 6 [4–9], p  <  0.001), higher blood lactate lev-
els (2.3 [1.5–4.9] vs. 2.0 [1.2–3.7] mmol/L, p  =  0.02) 
(Additional file 1: Fig. S1) and the further requirements 
for organ failure supports including vasopressive drugs 
(70 vs. 57.7%, p = 0.004), invasive mechanical ventilation 
(55.2 vs. 48.7%, p = 0.01) and renal replacement therapy 
(30.5 vs. 22.2%, p = 0.03).
The overall in-ICU and in-hospital mortality rates were 
28.9 and 41.4%, respectively. In univariate analysis, RBC 
transfusion within the first 48  h was associated with 
increased mortality at day 7 (20.5 vs. 13.3%, p  =  0.02), 
in the ICU (39 vs. 25.2%, p < 0.001) and in the hospital 
(51 vs. 36.6%, p < 0.001) (Table 2; Fig. 2a). After adjust-
ment with other relevant variables including the hemo-
globin level on ICU admission and septic shock, RBC 
transfusion was no longer associated with 7-day mortal-
ity (OR 1.11 [0.66–1.87], p = 0.7), but tended to be asso-
ciated with higher in-ICU and in-hospital mortality rate 
(OR 1.44 [0.94–2.21], p = 0.09 and OR 1.52 [1.03–2.26], 
p  =  0.03, respectively). Other variables associated with 
in-hospital mortality were poor performance status, 
severity on admission as assessed by SOFA score, alloge-
neic hematopoietic stem cell transplantation, increased 
time to ICU admission and invasive aspergillosis. Partial 
Fig. 1 Hemoglobin levels in non‑transfused (n = 421) and transfused 
(n = 210) patients. ICU intensive care unit, RBC red blood cell
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Table 1 Characteristics of patients without and with red blood cell transfusions at day 1/2
Characteristics No RBC transfusion  
(n = 421)
RBC transfusion  
(n = 210)
p
Demographics
 Age (years) 60 [49–71] 60 [49–69] 0.68
 Male gender 268 (63.7%) 138 (65.7%) 0.30
Comorbid illnesses
 Performance status 3–4 87 (20.7%) 51 (24.3%) 0.35
 Charlson comorbidity index 4 [3–6] 4 [2–5] 0.77
 Cardiovascular comorbidity 155 (36.8%) 77 (36.7%) 1
  Coronary disease 31 (7.3%) 19 (9.0%) 0.53
  Chronic heart failure 20 (4.8%) 14 (6.7%) 0.35
  Peripheral arterial disease 19 (4.5%) 6 (2.8%) 0.39
Underlying malignancy 0.01
 Non‑Hodgkin lymphoma 149 (35.4%) 53 (25.2%)
 Hodgkin lymphoma 13 (3.1%) 2 (1.0%)
 Chronic lymphocytic leukemia 37 (8.8%) 13 (6.2%)
 Acute lymphocytic leukemia 23 (5.5%) 20 (9.5%)
 Acute myeloid leukemia 88 (20.9%) 69 (32.3%)
 Chronic myeloid leukemia 8 (1.9%) 4 (1.9%)
 Myeloma 56 (13.3%) 26 (12.4%)
 Myelodysplastic syndrome 23 (5.5%) 12 (5.7%)
 Others 24 (5.7%) 11 (5.2%)
Time between diagnosis and ICU admission (days) 294 [38–1309] 199 [29–817] 0.06
Hematopoietic stem cell transplantation
 Autologous 50 (11.9%) 26 (12.4%) 0.72
 Allogeneic 77 (18.3%) 33 (15.7%) 0.49
Malignancy status
 Newly diagnosed 120 (28.6%) 70 (33.3%) 0.95
 Partial/complete remission 115 (27.5%) 54 (25.7%) 0.54
Time between hospital and ICU admissions (days) 6 [1–21] 8 [1–19] 0.38
ICU admission characteristics
 SOFA 6 [4–9] 8 [5–11] <0.001
 Hemoglobin (g/dL) 9.7 [8.7–11] 7.8 [7.1–8.8] <0.001
 Hemoglobin ranges [n (%)] 0.001
  >9 g/dL 259 (66.1%) 44 (21.9%)
  7–9 g/dL 126 (32.1%) 117 (58.2%)
  <7 g/dL 7 (1.8%) 40 (19.9%)
 Platelet count (G/L) 77 [32–170] 31 [16–63] <0.001
 Neutropenia 122 (29.0%) 107 (51.0%) <0.001
 Lactate level (mmol/L) 2.0 [1.2–3.7] 2.3 [1.5–4.9] 0.02
Source of infection
 Pneumonia 252 (59.9%) 106 (50.5%) 0.03
 Abdominal 15.7% 17.6% 0.61
 Urinary tract 26 (6.2%) 10 (4.8%) 0.59
 Catheter‑related 5.0% 3.3% 0.46
Pathogens
 Gram‑negative bacteria 108 (25.7%) 67 (31.9%) 0.12
 Gram‑positive bacteria 60 (14.3%) 21 (10.0%) 0.69
 Aspergillus 46 (10.9%) 23 (11.0%) 1.00
 Pneumocystis 20 (4.8%) 2 (1.0%) 0.02
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or complete remission was associated with improved sur-
vival (Table 3).  
In order to refine the statistical adjustment between 
non-transfused and transfused patients, we built a pro-
pensity score of being transfused during the first two 
days following ICU admission. The propensity score was 
based on hemoglobin level at the time of ICU admis-
sion and on the following characteristics: age, gender, 
performance status, days since hospital admission, allo-
geneic hematopoietic stem cell transplantation, hema-
tological malignancy type and status, time between its 
diagnosis and ICU admission, time between hospital 
and ICU admissions, neutropenia, aspergillosis, chemo-
therapy, admission SOFA score and septic shock. This 
score allowed matching 142 patients who did receive 
RBC transfusion as part of the initial resuscitation to 
142 counterparts who did not. As shown in Fig. 2b, pro-
pensity score-matched transfused and non-transfused 
patients displayed similar survival trends (OR for in-
hospital death 1.25 [0.75–2.05], p = 0.39). When includ-
ing all 631 patients in a weighting analysis, day 1/2 RBC 
transfusion was still associated with increased hospital 
mortality (OR 1.64 [1.05–2.57], p = 0.03).
Discussion
There is no doubt that the prognosis of critically ill 
patients with hematological malignancies has dramati-
cally improved, and admission to the ICU is now viewed 
as a bridge to cure rather than a terminal process. The 
reasons for this trend are multiple, including general 
improvements in the prognosis of cancer, better and 
early identification of patients likely to benefit from 
intensive care and advances in the management of acute 
life-threatening disorders [18]. However, severe infec-
tions resulting in shock and/or acute respiratory failure 
represent dreaded complications in cancer patients and 
still account for a large number of deaths regardless of 
the stage of malignancy. It is clear that cancer patients 
already benefited from advances in the field of sepsis, but 
it remains a major area for improvement for this vulnera-
ble population. Nevertheless, such immunocompromised 
patients were either underrepresented or even excluded 
from the leading clinical trials in severe sepsis and sep-
tic shock. Whether they are entitled to strictly similar 
management as non-immunocompromised patients is 
questionable.
The poor prognosis of hematological patients with 
severe sepsis is commonly attributed to the underly-
ing immune defects resulting in impaired and delayed 
pathogen clearance, but additional mechanisms related 
to the disease itself or to its treatment may also worsen 
organ failures. For instance, endothelial or cardiac tox-
icity by chemotherapy and radiotherapy may contribute 
to the pathophysiology of acute circulatory failure [19], 
while lactic acidosis may not only reflect systemic tissue 
hypoperfusion but might also result from altered metab-
olism of tumor cells. However, intensity and duration 
or vasopressor support appear quite similar in cancer 
patients, either untreated or treated with chemotherapy, 
and in patients free of cancer but harboring alternative 
comorbidities [20]. Furthermore, microvascular derange-
ments have been reported in non-septic patients with 
chemotherapy-induced neutropenia, albeit microcircula-
tory alterations induced by septic shock appeared quite 
similar in neutropenic and non-neutropenic patients 
[21]. Most importantly, cancer patients commonly dis-
play chronic anemia likely to contribute to the impaired 
oxygen delivery encountered in severe sepsis and septic 
shock and appear then liable to RBC transfusion early in 
the course of hemodynamic resuscitation.
The general practice of RBC transfusion in the ICU 
is guided by the apparently opposite objectives of pre-
serving an appropriate tissue oxygenation while mini-
mizing the number of packed red cells transfused. 
Table 1 continued
Characteristics No RBC transfusion  
(n = 421)
RBC transfusion  
(n = 210)
p
Life‑supporting interventions
 Vasopressive drugs 243 (57.7%) 147 (70%) 0.004
 Invasive ventilation 205 (48.7%) 116 (55.2%) 0.01
 Renal replacement therapy 92 (22.2%) 62 (30.5%) 0.03
Platelet transfusions
 Day 1 70 (16.6%) 96 (45.7%) <0.001
 Day 2 58 (13.7%) 82 (39.0%) <0.001
Mortality
 ICU mortality 106 (25.2%) 82 (39.0%) <0.001
 Hospital mortality 154 (36.6%) 107 (51.0%) <0.001
ICU intensive care unit, RBC red blood cell, SOFA sequential organ failure assessment
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Studies investigating RBC transfusion in the ICU have 
so far been performed in general populations in which 
anemia is mostly acquired during the ICU stay as a result 
of dilution and blood loss, associated with an impaired 
erythropoietic response. In 1999, the pivotal TRICC 
study by Hebert and colleagues showed that a restrictive 
Table 2 Characteristics of in-hospital survivors and deceased
ICU intensive care unit, RBC red blood cell, SOFA sequential organ failure assessment
Characteristics In-hospital survivors  
(n = 370)
In-hospital deceased  
(n = 261)
p
Demographics
 Age (years) 58.5 [47–67.75] 63 [52–71] 0.01
 Male gender 240 (64.9%) 166 (63.6%) 0.81
Comorbid illnesses
 Performance status 3–4 61 (16.5%) 77 (29.5%) 0.0001
 Charlson comorbidity index 4 [2–5] 4 [3–6] 0.008
Underlying malignancy 0.90
 Lymphoid disease 179 (48.4%) 131 (50.2%)
 Myeloid disease 121 (32.7%) 83 (31.8%)
Time between diagnosis and ICU admission (days) 91 [14; 444] 90 [11; 396] 0.58
Hematopoietic stem cell transplantation 0.04
 Autologous 52 (14.1%) 24 (9.2%)
 Allogeneic 55 (14.9%) 55 (21.1%)
Malignancy status 0.019
 Newly diagnosed 106 (28.7%) 84 (32.2%)
 Partial/complete remission 116 (31.4%) 53 (21.4%)
Time between hospital and ICU admissions (days) 4 [0–16] 9 [1–25] <0.0001
ICU admission characteristics
 SOFA score 6 [4–8] 8 [5–11.75] <0.0001
 Neutropenia 125 (33.8%) 104 (39.9%) 0.14
 Lactate (mmol/L) 1.9 (1.125–3.575) 2.4 [1.6–5.6] 0.0001
Hemoglobin level (g/dL)
 Day 1 9.2 [8–10.7] 8.9 [7.8–10.2] 0.02
 Day 2 9.2 [8.3–10.2] 9.1 [8.3–10] 0.33
 Day 3 9 [8.1–10] 8.9 [8.2–9.975] 0.88
 Day 7 8.8 [8.1–9.8] 8.8 [8.3–9.95] 0.53
RBC transfusion
 Day 1 and/or 2 103 (27.8%) 107 (41%) 0.0008
 Day 3 42 (12.4%) 39 (17.3%) 0.13
 Day 7 16 (10.6%) 21 (16.7%) 0.19
Source of infection
 Pneumonia 190 (51.4%) 68 (64.3%) 0.002
 Abdominal 69 (18.7%) 34 (13.0%) 0.076
 Urinary tract 21 (5.7%) 15 (5.8%) 1.00
 Catheter‑related 21 (5.7%) 7 (2.7%) 0.11
Pathogens
 Gram‑negative bacteria 101 (27.3%) 74 (28.4%) 0.84
 Gram‑positive bacteria 56 (15.1%) 25 (9.6%) 0.053
 Aspergillus 27 (7.3%) 42 (16.1%) 0.0008
 Pneumocystis 17 (4.6%) 5 (1.9%) 0.11
Life‑supporting interventions
 Vasopressive drugs 184 (49.7%) 206 (78.9%) <0.0001
 Invasive ventilation 124 (33.5%) 197 (75.5) <0.0001
 Renal replacement therapy 56 (15.4%) 98 (38.7%) <0.0001
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strategy of non-leucodepleted RBC transfusion to main-
tain hemoglobin above 7 g/dL was at least as effective as 
a liberal transfusion strategy aimed to maintain hemo-
globin >10 g/dL in critically ill patients [12]. As of today, 
the recommendations for RBC transfusion in the ICU 
remain largely based on this study. Of note, this study 
excluded patients with a previous history of chronic 
anemia.
However, some studies challenged the general imple-
mentation of this restrictive strategy and suggested that 
a higher transfusion threshold might be beneficial in sep-
tic patients for whom oxygen delivery is of paramount 
importance. This was first derived from the study by Riv-
ers and colleagues, in which most EGDT-treated patients 
had received RBC transfusion to maintain a hematocrit 
level above 30% [5]. Since then, three studies using pro-
pensity-adjusted analysis also reported that RBC trans-
fusion was associated with improved survival in septic 
shock [22–24]. Furthermore, a Brazilian monocenter 
randomized study reported that a liberal RBC transfu-
sion strategy (hemoglobin >9  g/dL) versus a restric-
tive strategy (hemoglobin >7 g/dL) improved survival in 
critically ill patients admitted to the ICU following major 
cancer surgery [25]. The reasons for this finding remain 
intriguing, but possibly related to a lower incidence of 
both cardiovascular complications and superinfections. 
The same team reported a benefit from a liberal trans-
fusion strategy applied throughout the ICU stay in solid 
cancer patients with septic shock [26]. A multicenter 
randomized Scandinavian study addressed the transfu-
sion policy in septic shock patients, of whom 7.5% had 
hematological malignancies and 9.5% had metastatic 
cancer. Patients were randomized to either a restrictive 
or a liberal transfusion policy to maintain hemoglobin 
levels higher than 7 or 9 g/dL, respectively [13]. Similar 
survival rates were reported in the restrictive and liberal 
randomization arms. Subgroup analysis in patients with 
Fig. 2 Survival estimates in non‑transfused and transfused patients. Crude (a) and propensity score‑adjusted (b) survival estimates in patients who 
did or did not receive red blood cell transfusion during the first two days of resuscitation. a Encompasses the whole cohort (631 patients distributed 
into 421 non‑transfused and 210 transfused). b Includes 142 transfused patients with 142 propensity score‑matched non‑transfused counterparts. 
ICU intensive care unit
Table 3 Determinants of  hospital mortality: multivariate 
analysis
All variables entered into the model appear in the table. Hosmer–Lemeshow 
goodness of fit of the multivariate model was tested on each imputed dataset, 
with p values ranging from 0.22 to 0.96
CI confidence interval, HSCT hematopoietic stem cell transplantation, ICU 
intensive care unit, RBC red blood cell, OR odds ratio, SOFA sequential organ 
failure assessment
Characteristics Odds ratio (95% CI) p
RBC transfusion at day 1/2 1.52 (1.03–2.26) 0.03
Hemoglobin level at ICU admission 1.0 (0.95–1.06) 0.87
Performance status 3–4 1.97 (1.29–3.02) 0.002
Lactate level at ICU admission 1.01 (0.96–1.05) 0.79
SOFA score at ICU admission 1.14 (1.1–1.21) <0.001
Septic shock 1.30 (0.86–1.96) 0.21
Allogeneic HSCT recipient 2.14 (1.28–3.57) 0.004
Remission 0.53 (0.34–0.84) 0.007
Time between hospital and ICU  
admissions >1 day
1.69 (1.14–2.51) 0.009
Invasive aspergillosis 1.91 (1.08–3.4) 0.02
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hematological malignancies or metastatic cancer also 
retrieved similar survival rates in both randomization 
arms [27]. However, it should be emphasized that most 
patients had already been efficiently resuscitated and 
restored tissue oxygenation at the time of randomization. 
Although this study suggests that a restrictive transfusion 
policy can be safely implemented in most patients with 
septic shock, we do think that it does not provide a defi-
nite answer for patients with persistent and/or marked 
circulatory failure.
The trend in increased mortality in transfused patients 
is the most intriguing result of our study. Although this 
is in line with several case–control studies which sug-
gested that RBC transfusion was associated with higher 
mortality and increased incidence of ICU-acquired com-
plications in critically ill patients, the interpretation of 
this finding deserves caution. On one hand, this could 
suggest that requirements of RBC transfusion, presum-
ably imposed by persistent tissue dysoxia, could repre-
sent a very potent prognostic factor even when adjusted 
to the classical determinants of death in this setting. On 
the other hand, there are considerable interindividual 
variations in the microcirculatory and tissue oxygena-
tion responses to RBC transfusion [28, 29]. Increase in 
blood viscosity by RBC transfusion and storage lesions 
can result in paradoxical impairment on microcirculation 
and tissue oxygenation. While not being immediately 
fully efficient for oxygen delivery to tissue, red cells may 
then sludge within capillaries, interact with endothelial 
cells and promote inflammatory processes [30, 31]. How-
ever, recent studies using leucodepleted packed red cells 
did not retrieve any impact of storage duration on resto-
ration of tissue oxygenation or survival status in critically 
ill patients with anemia [32, 33]. Finally, RBC transfusion 
may represent a risk factor for hospital-acquired infec-
tion as a result of transfusion-induced immunomodula-
tion [34, 35]. Although we could not reliably collect the 
incidence of ICU-acquired complications, it is notewor-
thy that the non-adjusted survival curves of transfused 
and non-transfused patients forked as early as three days 
after ICU admission, suggesting that the poor impact of 
RBC transfusion was related to early events rather than 
secondary ICU-acquired complications.
One strength of this study is the prospective collection 
of data, although it was a secondary analysis of a data-
base that was not designed to this specific aim. In gen-
eral, data from the first three days were complete and 
accurate, but data collected later on were less detailed. 
Thus, the estimation of packed red cells transfused 
within the first three days was accurate, whereas daily 
transfusions thereafter were not collected. Nonethe-
less, neither the volume of fluid loading nor the fluid 
balance was accurately recorded in the database. In the 
same way, the incidence of delayed ICU-acquired infec-
tious and non-infectious complications and the definite 
causes of death could not be reliably estimated. In the 
absence of guidelines, indications of RBC transfusion in 
this setting were probably quite inconsistent across cent-
ers. Hemoglobin levels in the RBC transfusion group 
were often higher than the recommended 7 g/dl thresh-
old. However, this was an observational study reflecting 
routine practice. With respect to the lower hemoglobin 
levels and the severity of circulatory dysfunctions in 
transfused patients, it is likely that physicians followed a 
common pragmatic decision-making process at the bed-
side, based not only on a sole hemoglobin level but also 
on markers of tissue dysoxia. However, such an obser-
vational study can only provide exploratory data and 
statistical link, but is no substitute to prospective inter-
ventional studies.
Conclusion
RBC transfusions are frequently used as part of the initial 
resuscitation of severe sepsis or septic shock in patients 
with hematological malignancies. Although RBC trans-
fusion was preferentially administrated to the most 
severe patients, we found it possibly associated with an 
increased risk of death. Since the definite indications of 
RBC transfusions in resuscitation of severe sepsis remain 
questionable, cancer patients with a high prevalence 
of underlying anemia represent a relevant subgroup to 
address this question in a prospective manner.
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